Boston Scientific Corporation $BSX Shares Acquired by Envestnet Asset Management Inc.

Envestnet Asset Management Inc. grew its position in Boston Scientific Corporation (NYSE:BSX) by 0.5% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 2,804,912 shares of the medical equipment provider’s stock after buying an additional 13,947 shares during the quarter. Envestnet Asset Management Inc. owned 0.19% of Boston Scientific worth $301,276,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also modified their holdings of BSX. 1248 Management LLC acquired a new stake in shares of Boston Scientific in the first quarter valued at $26,000. Y.D. More Investments Ltd acquired a new stake in shares of Boston Scientific in the first quarter valued at $27,000. Sound Income Strategies LLC grew its stake in shares of Boston Scientific by 90.9% in the second quarter. Sound Income Strategies LLC now owns 252 shares of the medical equipment provider’s stock valued at $27,000 after buying an additional 120 shares in the last quarter. Princeton Global Asset Management LLC acquired a new position in Boston Scientific during the 2nd quarter worth $32,000. Finally, Oliver Lagore Vanvalin Investment Group acquired a new position in Boston Scientific during the 2nd quarter worth $37,000. 89.07% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

BSX has been the subject of several analyst reports. Oppenheimer raised Boston Scientific from a “market perform” rating to an “outperform” rating and boosted their target price for the stock from $118.00 to $125.00 in a research note on Monday, September 8th. Wells Fargo & Company boosted their target price on Boston Scientific from $124.00 to $125.00 and gave the stock an “overweight” rating in a research note on Thursday. Canaccord Genuity Group reissued a “buy” rating and set a $132.00 target price on shares of Boston Scientific in a research note on Thursday. Truist Financial boosted their target price on Boston Scientific from $129.00 to $130.00 and gave the stock a “buy” rating in a research note on Thursday. Finally, Erste Group Bank cut Boston Scientific from a “buy” rating to a “hold” rating in a research note on Friday, October 3rd. Two investment analysts have rated the stock with a Strong Buy rating, twenty-one have issued a Buy rating and two have issued a Hold rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus price target of $123.77.

Boston Scientific Trading Down 1.3%

NYSE:BSX opened at $101.08 on Monday. The stock has a 50-day simple moving average of $101.14 and a 200-day simple moving average of $102.12. The stock has a market cap of $149.78 billion, a P/E ratio of 54.06, a P/E/G ratio of 2.04 and a beta of 0.61. Boston Scientific Corporation has a 1 year low of $80.64 and a 1 year high of $109.50. The company has a debt-to-equity ratio of 0.49, a quick ratio of 0.82 and a current ratio of 1.37.

Boston Scientific (NYSE:BSX) last released its quarterly earnings data on Wednesday, October 22nd. The medical equipment provider reported $0.75 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.71 by $0.04. The business had revenue of $5.07 billion during the quarter, compared to analysts’ expectations of $4.97 billion. Boston Scientific had a return on equity of 19.74% and a net margin of 14.43%.The business’s quarterly revenue was up 20.3% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.63 EPS. Boston Scientific has set its FY 2025 guidance at 3.020-3.040 EPS. Q4 2025 guidance at 0.770-0.790 EPS. As a group, analysts anticipate that Boston Scientific Corporation will post 2.85 earnings per share for the current fiscal year.

Insider Activity at Boston Scientific

In related news, EVP Arthur C. Butcher sold 17,313 shares of the company’s stock in a transaction dated Friday, August 1st. The stock was sold at an average price of $104.63, for a total value of $1,811,459.19. Following the completion of the sale, the executive vice president directly owned 23,600 shares of the company’s stock, valued at $2,469,268. This represents a 42.32% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Joseph Michael Fitzgerald sold 50,000 shares of the company’s stock in a transaction dated Wednesday, October 1st. The shares were sold at an average price of $98.47, for a total value of $4,923,500.00. Following the completion of the sale, the executive vice president directly owned 178,342 shares of the company’s stock, valued at approximately $17,561,336.74. This trade represents a 21.90% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 170,214 shares of company stock valued at $17,548,337 in the last three months. 0.50% of the stock is currently owned by company insiders.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.